NX-07

NX-07 is a preclinical nanobody candidate developed by Beijing Neoletix Biological Technology using its proprietary NanoT platform. While the drug is primarily listed in the company's pipeline for the treatment of thrombosis, its described mechanism involves engaging the tumor microenvironment (TME). This discrepancy in the pipeline documentation suggests a potential multi-functional role or a specific target within the TME that also plays a role in thrombotic processes. As a nanobody, NX-07 is a single-domain antibody fragment (VHH) designed to leverage the high stability and tissue penetration characteristic of these molecules.